| HOME >> BIOLOGY >> TECHNOLOGY |
Misaligned research, medical challenges and harsh economics are thwarting efforts to slow the destructive course of Alzheimer's disease in the United States, according to a trio of nationally regarded Alzheimer's researchers writing a "Perspective" in Thursday's (Jan. 27) issue of the journal Neuron.
The foremost obstacle is that the most promising preventive strategies are being tested in patients firmly in the grip of Alzheimer's disease the ones least likely to be helped.
The approach would be similar to testing statins drugs widely used to prevent heart disease in patients who are already in cardiac arrest, according to Dr. Todd Golde, director of the UF College of Medicine's Center for Translational Research in Neurodegenerative Disease.
With Dr. Edward Koo of the University of California, San Diego, and Dr. Lon S. Schneider of the Keck School of Medicine at the University of Southern California, Golde pointed to a lack of alignment between studies in human volunteers, which focus on treatment, and preclinical laboratory studies, which are aimed at prevention.
"If we do the right types of clinical studies, we have the ability to move toward prevention, which would have a huge impact on this disease," said Golde, a professor in the department of neuroscience at UF's McKnight Brain Institute. "But we have to overcome our 'prevention versus treatment' dilemma. We already have more than 5 million people affected, and half of people in nursing homes, or more, have Alzheimer's disease. As society ages, we are just going to continue to see Alzheimer's drain the economy and the quality of human life."
Without medical breakthroughs, a projected 7.7 million patients in the U.S. will have Alzheimer's by 2030, according to the Alzheimer's Association. That number will grow to between 11 million and 16 million by 2050.
Researchers say solving the treatment-prevention problem will require the development of
'/>"/>
| Contact: John Pastor jdpastor@ufl.edu 352-273-5815 University of Florida Source:Eurekalert |